AEMD Aethlon Medical Inc.

Aethlon Medical Inc.

Medical/Dental Instruments

Health Care

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

IPO Year:

Exchange: NASDAQ

Website: aethlonmedical.com

Peers

$IBIO

$RZLT

Recent Analyst Ratings for Aethlon Medical Inc.

Date	Price Target	Rating	Analyst
6/25/2021	$5.00 → $9.00	Buy	HC Wainwright & Co.

See more ratings

Aethlon Medical Inc.

Peers

Recent Analyst Ratings for Aethlon Medical Inc.

Aethlon Medical Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

HC Wainwright & Co. reiterated coverage on Aethlon Medical with a new price target

HC Wainwright & Co. initiated coverage on Aethlon Medical with a new price target

Aethlon Medical Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Rossetti Angela was granted 142,857 shares, increasing direct ownership by 71% to 343,400 units (SEC Form 4)

Director Gikakis Nicolas was granted 142,857 shares, increasing direct ownership by 454% to 174,320 units (SEC Form 4)

Director Broenniman Edward G was granted 142,857 shares, increasing direct ownership by 367% to 181,741 units (SEC Form 4)

Director Shah Chetan gave a grant of 142,857 shares, decreasing direct ownership by 45% to 174,233 units (SEC Form 4)

Director Broenniman Edward G covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 4% to 38,884 units (SEC Form 4)

Director Shah Chetan covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 9% to 31,376 units (SEC Form 4)

Director Gikakis Nicolas covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 9% to 31,463 units (SEC Form 4)

Director Broenniman Edward G covered exercise/tax liability with 1,645 shares, decreasing direct ownership by 4% to 40,529 units (SEC Form 4)

Director Shah Chetan covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 9% to 34,665 units (SEC Form 4)

Director Gikakis Nicolas covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 9% to 34,752 units (SEC Form 4)